Evidence map›Paper›PMID 35867672›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care With Standard Human Immunodeficiency Virus (HIV) Viral Load Monitoring in Nigeria.

Charlotte Chang, Oche Agbaji, Kiren Mitruka, Bola Olatunde, Halima Sule, Titus Dajel, Aaron Zee, Mukhtar L Ahmed, Isah Ahmed, Prosper Okonkwo and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03533868 (Reaching 90% Target of HIV Viral Suppression), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03533868 nacompletednot on this map

Reaching 90% Target of HIV Viral Suppression: The Role of Point-of-Care Viral Load Monitoring in Resource-Constrained Settings in Nigeria

TypeinterventionalSponsorHarvard School of Public Health (HSPH)Ran2018 to 2021Enrolled543ConditionsHIV/AIDSArmsPoint-of-care viral load monitoring test
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Charlotte ChangDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Oche AgbajiJos University Teaching Hospital, Jos, Nigeria.
Kiren MitrukaCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Bola OlatundeJos University Teaching Hospital, Jos, Nigeria.
Halima SuleJos University Teaching Hospital, Jos, Nigeria.
Titus DajelComprehensive Health Centre Zamko, Jos, Nigeria.
Aaron ZeeCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Mukhtar L AhmedCenters for Disease Control and Prevention, Abuja, Nigeria.
Isah AhmedAPIN Public Health Initiatives, Abuja, Nigeria.
Prosper OkonkwoAPIN Public Health Initiatives, Abuja, Nigeria.
Beth ChaplinDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Phyllis KankiDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

Funding

CDC HHS GH-16-005CGH CDC HHS U01 GH002109
6 · The paper itself

Abstract

backgroundPoint-of-care (POC) viral load (VL) tests provide results within hours, enabling same-day treatment interventions. We assessed treatment outcomes with POC vs standard-of-care (SOC) VL monitoring.

methodsWe implemented a randomized controlled trial at an urban and rural hospital in Nigeria. Participants initiating antiretroviral therapy (ART) were randomized 1:1 for monitoring via the POC Cepheid Xpert or SOC Roche COBAS (v2.0) HIV-1 VL assays. Viral suppression (VS) and retention in care at 12 months were compared via intention-to-treat (ITT) and per-protocol (PP) analyses. Post-trial surveys for POC patients and healthcare workers (HCWs) evaluated acceptability.

resultsDuring April 2018-October 2019, 268 SOC and 273 POC patients enrolled in the trial. Viral suppression at <1000 copies/mL at 12 months was 59.3% (162/273) for POC and 52.2% (140/268) for SOC (P = .096) in ITT analysis and 77.1% (158/205) for POC and 65.9% (137/208) for SOC (P = .012) in PP analysis. Retention was not significantly different in ITT analysis but was 85.9% for POC and 76.9% for SOC (P = .02) in PP analysis. The increased VS in the POC arm was attributable to improved retention and documentation of VL results. POC monitoring was preferred over SOC by 90.2% (147/163) of patients and 100% (15/15) of HCWs thought it facilitated patient care.

conclusionsPOC VL monitoring did not improve 12-month VS among those with results but did improve retention and VS documentation and was preferred by most patients and HCWs. Further research can inform best POC implementation conditions and approaches to optimize patient care. CLINICAL TRIALS REGISTRATION: NCT03533868.

Indexed as

Anti-HIV AgentsHIV InfectionsHIVHumansNigeriaPoint-of-Care SystemsViral LoadAnti-HIV AgentsHIVoutcomespoint-of-carerandomized controlled trialviral load

Identifiers

PMID35867672
PMCPMC11150517

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.